This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Mar 2012

Byetta Approved for Use with Basal Insulin in Europe

Amylin and Eli Lilly announced the marketing authorization from the European Commission for the use of BYETTA with basal insulin.

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced that the European Commission has granted marketing authorization to BYETTA (exenatide twice-daily) as an adjunctive therapy to basal insulin, with or without metformin and/or Actos? (pioglitazone), for the treatment of type 2 diabetes in adults who have not achieved adequate glycemic control with these agents.


"The marketing authorization for the use of BYETTA with basal insulin provides a new option for the many patients with type 2 diabetes who are not achieving treatment goals," said Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals.


"In a clinical trial, patients using fixed-dose BYETTA with titrated basal insulin achieved better postprandial and ove

Related News